- Conditions
- Chronic Gout
- Interventions
- SEL-212 low-dose, SEL-212 high-dose, Placebo
- Drug · Other
- Lead sponsor
- Swedish Orphan Biovitrum
- Industry
- Eligibility
- 19 Years to 80 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 30
- States / cities
- Clearwater, Florida • DeBary, Florida • Hialeah, Florida + 24 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chronic Gout
- Interventions
- SEL-212 low-dose, SEL-212 high-dose, Normal Saline
- Drug · Other
- Lead sponsor
- Swedish Orphan Biovitrum
- Industry
- Eligibility
- 19 Years to 80 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 40
- States / cities
- Anniston, Alabama • Sun City, Arizona • Covina, California + 36 more
- Conditions
- Refractory Chronic Gout
- Interventions
- Pegloticase
- Biological
- Lead sponsor
- Horizon Pharma Rheumatology LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Covina, California + 59 more
- Conditions
- Chronic Gout Refractory to Conventional Therapy
- Interventions
- pegloticase 8 mg i.v.
- Drug
- Lead sponsor
- Savient Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Wheaton, Maryland • Durham, North Carolina + 1 more
- Conditions
- Chronic Gout
- Interventions
- SEL-212, KRYSTEXXA®
- Drug
- Lead sponsor
- Selecta Biosciences, Inc.
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 43
- States / cities
- Anniston, Alabama • Sun City, Arizona • Little Rock, Arkansas + 35 more